News
Air pollution linked to drop in live births among IVF patients
The study findings have emphasised the need for ongoing attention to environmental factors in reproductive health
Exposure to fine particulate matter (PM) prior to the retrieval of oocytes during IVF can reduce the odds of achieving a live birth by almost 40 per cent, new research has shown.
The study, presented at the ESHRE 40th annual meeting in Amsterdam, analysed PM10 exposure in the two weeks leading up to oocyte collection and found that the odds of a live birth decreased by 38 per cent when comparing the highest quartile of exposure to the lowest quartile.
Conducted over an eight-year period in Perth, Australia, the research analysed 3,659 frozen embryo transfers from 1,836 patients.
The study examined air pollutant concentrations over four exposure periods prior to oocyte retrieval – 24 hours, two weeks, four weeks, and three months – with models created to account for co-exposures.
Increasing PM2.5 exposure in the three months prior to oocyte retrieval was also associated with decreased odds of live birth, falling from 0.90 in the second quartile to 0.66 in the fourth quartile.
Importantly, the negative impact of air pollution was observed despite excellent overall air quality during the study period, with PM10 and PM2.5 levels exceeding WHO guidelines on just 0.4 per cent and 4.5 per cent of the study days, respectively.
“This is the first study that has used frozen embryo transfer cycles to separately analyse the effects of pollutant exposure during the development of eggs and around the time of embryo transfer and early pregnancy,” explained Dr Sebastian Leathersich, lead author of the study.
“We could therefore evaluate whether pollution was having an effect on the eggs themselves, or on the early stages of pregnancy.
“Even in a part of the world with exceptional air quality, there is a strong negative correlation between the amount of air pollution and the live birth rate in frozen embryo transfer cycles. Minimising pollutant exposure must be a key public health priority,” he added.
Professor Dr Anis Feki, chair-elect of ESHRE, said: “This important study highlights a significant link between air pollution and lower IVF success rates, with a notable reduction in live births associated with higher particulate matter exposure before oocyte retrieval.
“These findings emphasise the need for ongoing attention to environmental factors in reproductive health.”
To receive the Femtech World newsletter, sign up here.
Insight
Topical HRT protects bone density in women with period loss – study
Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.
The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.
Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.
Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.
The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.
Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.
“Our study provides much needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.
“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”
When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.
The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.
They found no significant benefit for oral contraceptive pills or oral hormone therapy.
A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.
Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.
“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.
“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”
Insight
AI cuts interval breast cancers in Swedish trial
Mental health
Fear of ageing may age women faster, study suggests
-
Hormonal health4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026







1 Comment